Furthermore, the bromodomain and extraterminal domain (BET) inhibitor JQ1 was shown to significantly suppress CCBE1 transcription, inhibit VEGF-C proteolysis, and reduce tumor lymphangiogenesis both in vitro and in vivo [96]. This evidence concerns the gene VEGFC and neoplasm.